This may be partially inferred from a recent work suggesting a link between the generation of reactive dopamine metabolites which are autotoxic to dopaminergic neurons and the inhibition of ALDH [37], and is corroborated by the findings of Dolma S et al., that recently highlighted the prognostic relevance of DRD4 expression in patients with GBM based on analysis of The Cancer Genome Atlas (TCGA) data, and suggested that the inhibition of DRD4 can attenuate the proliferation and survival of GSCs by disrupting platelet-derived growth factor receptor β (PDGFRβ)-ERK1/2 and mTOR signaling [38]. This evidence concerns the gene MTOR and glioblastoma.